...
首页> 外文期刊>mSphere >Restricted Sequence Variation in Streptococcus pyogenes Penicillin Binding Proteins
【24h】

Restricted Sequence Variation in Streptococcus pyogenes Penicillin Binding Proteins

机译:链球菌的受限制序列变异性青霉素结合蛋白

获取原文
           

摘要

A recent clinical report has linked Streptococcus pyogenes β-lactam antibiotic resistance to mutation in the penicillin binding protein (PBP) PBP2x. To determine whether this is an isolated case or reflects a broader prevalence of mutations that might confer reduced β-lactam susceptibility, we investigated the relative frequency of PBP sequence variation within a global database of 9,667 S. pyogenes isolates. We found that mutations in S. pyogenes PBPs (PBP2x, PBP1a, PBP1b, and PBP2a) occur infrequently across this global database, with fewer than 3 amino acid changes differing between 99% of the global population. Only 4 of the 9,667 strains contained mutations near transpeptidase active sites of PBP2x or PBP1a. The reported PBP2x T553K substitution was not identified. These findings are in contrast to those of 2,520 S. pneumococcus sequences where PBP mutations are relatively frequent and are often located in key β-lactam binding pockets. These data, combined with the general lack of penicillin resistance reported in S. pyogenes worldwide, suggests that extensive, unknown constraints restrict S. pyogenes PBP sequence plasticity. Our findings imply that while heavy antibiotic pressure may select for mutations in the PBPs, there is currently no evidence of such mutations becoming fixed in the S. pyogenes population or that mutations are being sequentially acquired in the PBPs. IMPORTANCE β-Lactam antibiotics are the first-line therapeutic option for Streptococcus pyogenes infections. Despite the global high prevalence of S. pyogenes infections and widespread use of β-lactams worldwide, reports of resistance to β-lactam antibiotics, such as penicillin, have been incredibly rare. Recently, β-lactam resistance, as defined by clinical breakpoints, was detected in two clinical S. pyogenes isolates with accompanying mutations in the active site of the penicillin binding protein PBP2x, raising concerns that β-lactam resistance will become more widespread. We screened a global database of S. pyogenes genome sequences to investigate the frequency of PBP mutations, identifying that PBP mutations are uncommon relative to those of Streptococcus pneumoniae . These findings support clinical observations that β-lactam resistance is rare in S. pyogenes and suggest that there are considerable constraints on S. pyogenes PBP sequence variation.
机译:最近的临床报告链接化脓性链球菌β内酰胺类抗生素耐药突变的青霉素结合蛋白(PBP)PBP2X。为了确定这是否是一个孤立的情况下,或反映了可能共同赋予减少β内酰胺易感性突变的更广泛的流行率,我们调查的9667个化脓性链球菌菌株的全球数据库内PBP序列变化的相对频率。我们发现在化脓性链球菌的PBPs(PBP2X,PBP1A,PBP1b和PBP2a的)的突变很少发生过这个全球数据库,少于3个氨基酸的全球人口> 99%之间不同的氨基酸变化。只有9,667株4包含近PBP2X或PBP1A的转活性位点的突变。报告PBP2X T553K取代没有确定。这些发现与那些2520个S.肺炎球菌序列的其中PBP的突变是相对频繁的,并且通常位于键β内酰胺结合口袋。这些数据,与一般缺乏青霉素抗性的组合报道全世界S.酿脓链球菌,表明广泛的,未知的约束限制化脓性链球菌PBP序列可塑性。我们的发现意味着,当在重抗生素压力可以在的PBPs突变选择,目前还没有这样的突变的证据变得固定在化脓性链球菌群或该突变在被的PBPs顺序地获取。重要性β内酰胺类抗生素是酿脓链球菌感染的一线治疗选择。尽管全球化脓性链球菌感染和广泛使用的全球高患病率β内酰胺类,以β内酰胺类抗生素,如青霉素耐药的报道,已经令人难以置信的罕见。最近,β内酰胺抗性,通过临床断点所限定,以两个临床酿脓链球菌分离株检测到与在所述青霉素结合蛋白PBP2X的活性位点的突变伴随,令人担忧的是β内酰胺电阻将变得更加普遍。我们筛选化脓性链球菌的全球数据库的基因组序列进行调查PBP突变的频率,识别PBP突变是相对于那些肺炎链球菌少见。这些发现支持临床观察:β内酰胺抗性是化脓性链球菌稀有表明,有相当大的制约上化脓性链球菌PBP序列变异。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号